Effectiveness of the MULTIPAP Plus intervention in youngest-old patients with multimorbidity and polypharmacy aimed at improving prescribing practices in primary care: study protocol of a cluster randomized trial

Isabel del Cura-González 1,2,3,4,5*, Juan A. López-Rodríguez 1,2,3,4,5,6, Francisca Leiva-Fernández 3,5,7,8,9, Luis A. Gimeno-Feliú 3,5,10,11,12, Victoria Pico-Sole 3,5,12,13, Mª. Josefa Bujalance-Zafra 7,14, Miguel Domínguez-Santaella 7,14, Elena Polentinos-Castro 1,2,3,4,5, Beatriz Poblador-Plou 3,5,12, Paula Ara-Bardají 3,5,12, Mercedes Aza-Pascual-Salcedo 3,5,12,15, Marisa Rogero-Blanco 3,4,5,6, Marcos Castillo-Jiménez 7,16, Cristina Lozano-Hernández 1,3,5,17, Antonio Gimeno-Miguel 3,5,12, Francisca González-Rubio 3,5,12,18, Rodrigo Medina-García 1,4,5,6,17, Alba González-Hevilla 7, Mario Gil-Conesa 19, Jesús Martín-Fernández 2,3,4,5,20, José M. Valderas 21, Alessandra Marengoni 22, Christiane Muth 23, J. Daniel Prados-Torres 3,5,7,8,9†, Alexandra Prados-Torres 3,5,12†, and MULTIPAP PLUS Group

Abstract

Background: The progressive ageing of the population is leading to an increase in multimorbidity and polypharmacy, which in turn may increase the risk of hospitalization and mortality. The enhancement of care with information and communications technology (ICT) can facilitate the use of prescription evaluation tools and support system for decision-making (DSS) with the potential of optimizing the healthcare delivery process.

Objective: To assess the effectiveness and cost-effectiveness of the complex intervention MULTIPAP Plus, compared to usual care, in improving prescriptions for young-old patients (65-74 years old) with multimorbidity and polypharmacy in primary care.

Methods/design: This is a pragmatic cluster-randomized clinical trial with a follow-up of 18 months in health centres of the Spanish National Health System. Unit of randomization: family physician. Unit of analysis: patient.

* Correspondence: Isabel.cura@salud.madrid.org
† J. Daniel Prados-Torres and Alexandra Prados-Torres share senior co-authorship.
1 Research Unit, Primary Care Assistance Management, Madrid Health Service, Madrid, Spain
Full list of author information is available at the end of the article

© The Author(s) 2022 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Population: Patients aged 65–74 years with multimorbidity (≥ 3 chronic diseases) and polypharmacy (≥ 5 drugs) during the previous 3 months were included.

Sample size: n = 1148 patients (574 per study arm).

Intervention: Complex intervention based on the ARIADNE principles with three components: (1) family physician (FP) training, (2) FP-patient interview, and (3) decision-making support system.

Outcomes: The primary outcome is a composite endpoint of hospital admission or death during the observation period measured as a binary outcome, and the secondary outcomes are number of hospital admission, all-cause mortality, use of health services, quality of life (EQ-5D-5L), functionality (WHODAS), falls, hip fractures, prescriptions and adherence to treatment. Clinical and sociodemographic factors will be explanatory variables.

Statistical analysis: The main result is the difference in percentages in the final composite endpoint variable at 18 months, with its corresponding 95% CI. Adjustments by the main confounding and prognostic factors will be performed through a multilevel analysis. All analyses will be carried out in accordance to the intention-to-treat principle.

Discussion: It is important to prevent the cascade of negative health and health care impacts attributable to the multimorbidity-polypharmacy binomial. ICT-enhanced routine clinical practice could improve the prescription process in patient care.

Trial registration: ClinicalTrials.gov NCT04147130. Registered on 22 October 2019

Keywords: Multimorbidity, Patient-centred care, Polypharmacy, Medication reconciliation, Decision-making, Computer-assisted, Primary health care, Cluster randomized controlled trial

Contributions to the literature

- There is lack of evidence about the effectiveness of interventions in primary care to prevent the cascade of negative health care impacts attributable to the multimorbidity-polypharmacy binomial.
- There are conflicting results on the effectiveness of decision support systems (DSS) to improve medication appropriateness. MULTIPAP-PLUS complex intervention combines a family physician training, a specific type of FP-patient interview, and a DSS to help family physicians.
- Medical record-implemented DSS could be a tool of great potential, and a co-designed DSS has been adapted to the conditions of clinical practice inside case report forms.

Background

The progressive ageing of the population leads to an increase in multimorbidity, defined as ≥ 2 concurrent chronic medical conditions or ≥ 3 if a more specific threshold is considered to identify patients with complex health needs [1, 2]. In Spain, the average number of chronic problems in individuals > 75 years of age is 3.2; however, these patients constitute only part of the population with multimorbidity; among so-called older adults (65–74 years), it is 2.8 [3]. The importance of multimorbidity lies in its progressive increase with age [3] and its negative impact on health, reducing the quality of life and functional capacity of those who suffer from it. Likewise, it is associated with an increase in polypharmacy, hospitalizations, surgical complications, and mortality and, consequently, with a greater use of health services and therefore greater costs for health systems [4–7].

Within the framework of multimorbidity, polypharmacy acquires special importance. It is defined as the simultaneous consumption of ≥ 5 drugs and is considered the main determinant of potentially inappropriate prescription (PIP) in the elderly; this term encompasses excessive, incorrect, and insufficient prescriptions [8, 9]. Currently, it is estimated that 40% of the elderly population are polymedicated, having 36.5% of them PIP. This entails an increased risk of drug interactions and adverse drug reactions and therefore a low adherence and under-use of necessary treatments [10]. As people age, their risk of hospitalizations increases, as does their risk of fractures and therefore morbidity [11, 12] and mortality [7, 13]. It is estimated that 35% of elderly polymedicated patients in primary care (PC) develop some adverse effects, with 48.2% of adverse effects related to medication use and 59.1% of these being preventable [14, 15].

To quantify and reduce PIPs in complex patients, various measurement methods have been proposed: explicit, based on the properties of the drugs (BEERS and STOPP/START criteria), and implicit, based on the clinical judgement of the physician, who considers the overall situation of the patient and if the prescription responds to an indication or need, with the Medication Adequacy Index (MAI) being the most accepted method
[16–18]. On the other hand, to improve polypharmacy, interventions at various scales have been proposed, for example (a) the professional level (educational programmes for prescribers or consumers); (b) the organizational level (use of electronic medical records, feedback to reduce pharmacological interactions, continuous review of medications, and decision support systems in the care process—DSS); (c) the patient level (education on the use of medications and treatment objectives); and (d) the financial level (prescribed incentives and regulatory interventions) [19].

In recent years, the management of patients with multimorbidity has been studied to provide evidence in the context of European health systems [20]. Spain has implemented the MULTIPAP intervention [21, 22], a complex intervention in the elderly population with multimorbidity and polypharmacy. The MULTIPAP intervention based on the Ariadne principles, which includes international guidelines for the treatment of patients with multimorbidity [21, 23], is effective in improving the appropriateness of medication at 12 months, although we should be cautious in the interpretation of the results given the paucity of evidence for the clinical benefit of the observed change in MAI. The MULTIPAP formative intervention provides clues for approaching this type of patient and identifies areas of improvement in training content. Along these lines, a Cochrane systematic review [24] that evaluates interventions for the management of patients with multimorbidity supports the need to generate more evidence to determine what specific training physicians need in the approach of these patients [25].

In this way, the incorporation of Information and Communication Technologies (ICT) in patient care is an opportunity to introduce medication evaluation tools such as DSS to optimize the care process. The DSS are considered a promising technology that improves medical care and the quality of prescription and reduces prescribing errors. However, more quality studies are needed to establish evidence of its effectiveness and cost-effectiveness in conditions of routine clinical practice [26, 27]. At the European level, some initiatives have been launched that attempt to overcome these limitations [28].

Among the tools available in Spain, CheckTheMeds® [29, 30] is an DSS designed as a health care tool that globally processes demographic, clinical and pharmacological data to detect issues related to medications (underdosing, overdosing, duplicates, therapeutic inertia, allergy alerts, drug-drug and drug-disease interactions, including inappropriate drug criteria, etc.). Its recommendations are based on the best available evidence. This tool has already been incorporated into some hospital pharmacy and PC services to generate treatment review reports that are subsequently sent to doctors. In our group within the MULTIPAP intervention, we tested the tool, offering proposals for improving and establishing a framework of collaboration with the platform that allows the use of its full potential for research studies in the field of PC [31, 32]. After the experience with the MULTIPAP project, the MULTIPAP Plus intervention was developed, introducing organizational measures that family physicians (FPs) have identified as essential. These include the inclusion of a DSS in the care process and its link with clinically relevant processes for patients, as well as the study of the economic costs involved in these clinical processes in the health system.

Although DSS may reduce PIPs, interventions in PC focused on patients with multimorbidity and polypharmacy with patient-relevant outcomes as hospital admission, mortality and quality of life between others are a priority, and several systematic reviews agree on the importance of implementing well-designed RCTs that incorporate outcome variables of clinical relevance for the patient, as well as the socioeconomic impact [24, 33].

**Aim**

**Primary**

The main objective is to evaluate the effectiveness of the complex intervention MULTIPAP Plus, in improving prescriptions to a young-old population (65–74 years) with multimorbidity and polypharmacy measured with a composite endpoint of hospital admission or death at 18 months, compared with usual care.

**Secondary**

1. To evaluate the effectiveness of MULTIPAP Plus, measured as hospitalizations and/or all-cause mortality compared to those for routine practice at 12 months, as well as drug safety, use of services, quality of life of the patient measured with the EQ-5D-5L, disability, number of fractures, and adherence to treatment.
2. To study the cost-utility ratio for the intervention compared to usual care.
3. To describe the usability, adherence, and satisfaction with the DSS CheckTheMeds®.

**Methods**

**Design**

Pragmatic parallel two-arm, superiority, community-based cluster-randomized controlled clinical trial with a follow-up of 18 months. The unit of randomization is the FP, and the unit of analysis is the patient. The cost-utility study will be carried out from the perspective of the Spanish National Health System with a time horizon of 2 years.
CONSERVE-SPRIT has been used for reporting trial protocol instead of SPIRIT since MULTIPAP Plus had been suspended because of COVID-19 from March 2020 to May 2021 and methodologic modifications were made (Additional file 1: CONSERVE-SPRIT checklist; Additional file 2: SPIRIT Trial Modifications in Extenuating Circumstance). This situation has been notified and updated in the trial registry.

Scope of study
The scope of study is primary care within the Spanish National Health System. The Spanish National Health System provides first contact, comprehensive, continuous, coordinated care (which is free at the point of care) to define a population served by primary care centres. Patients have named family physicians who are responsible for delivering and coordinating their care.

Study population
The study population includes patients between 65 and 74 years with multimorbidity and polypharmacy attending in primary care health centres in three autonomous communities Aragón, Madrid, and Andalusia.

**FPs inclusion criteria:**
- Stable work situation, without intention to leave the position during the study.
- Agree to participate and sign the informed consent form

**Patient selection criteria:**
**Inclusion criteria:**
- Age: 65–74 years
- Multimorbidity: ≥ 3 chronic diseases
- Polypharmacy: ≥ 5 drugs prescribed for at least three months prior to inclusion in the study
- Having visited/contacted their family physician at least once in the last year
- Able to follow the requirements of the study
- Agree to participate and sign the informed consent form

**Exclusion criteria:**
- Institutionalized patients
- Life expectancy of less than 12 months based on their doctor
- Physical or mental illness that in the opinion of their doctor does not allow them to follow the study requirements.

**Sample size**
It was calculated under the hypothesis that the intervention would result in a difference of at least six percentage points in the combined variable (hospitalizations and/or all-cause mortality) between the study groups. According to previous studies, in the age range of 65 to 75 years, the criterion incidence of the estimated primary outcome variable was 16% [23, 34]. Considering a power of 80%, an alpha error of 5% and assuming simple random sampling, the required sample size would be 984 patients (492 patients per group).

The appropriate sample size for this type of design depends on the average size of the cluster and the degree of correlation between the individuals in the cluster. Consequently, it is necessary to adjust the sample size calculated according to the design effect (DE). An average group size of eight patients per FP and an intraclass correlation coefficient of 0.02 [35] produces the following (DE = 1 + (5–1) × 0.02 = 1.08), giving a sample size, corrected for design effect, of 1063 patients. Assuming a loss rate of 8%, the final sample size required is 1148 patients (574 per group).

Recruitment
MULTIPAP Plus has a group of 120 FPs who previously participated in the MULTIPAP project; voluntary participation has been proposed to this group and another FPs working in PC health centres in Aragón, Madrid, and Andalusia. Strategies to improve protocol adherence of FP will be considered (e.g. individual follow-up of protocol’s achievements and recognition via e-mail, offer to participate as co-authors in scientific papers, certified training sessions).

Patients will be selected by random sampling from the list of patients who meet the inclusion criteria. Subsequently, each FP will invite the listed patients, when the patient agrees to participate, the FP will inform them in detail about the study and confirm the inclusion/exclusion criteria and obtain the patient’s written informed consent. If they do not agree to participate, data on the patient’s age, sex, and reason for nonparticipation will be collected (see Fig. 1, flowchart).

The selection of professionals was carried out in the third quarter of 2019. The recruitment of patients began in November 2019 and was suspended in March 2020. Considering the epidemiological situation in Spain, and the reorganization of health services including primary care, it was not possible to restart the study until May 2021. In that month, the situation of the family physicians was reviewed, and the commitment was updated, as well as the situation of the patients recruited between November 2019 and February 2020.

Randomization
The unit of randomization is the FP, and the unit of analysis is the patient. The randomization of FPs will be achieved using the treatment assignment module of
Epidat® 4.1; the proposed intervention will be considered the treatment, and usual care will be considered the control. To guarantee an equal number of FPs in each group (intervention and control), the option “balanced groups” will be selected. Once all participating FPs have selected their patients and have collected the corresponding initial data, the Research Unit, Primary Care Management of Madrid, will randomize them centrally. Subsequently, each FP will receive the information of the study group to which they have been assigned, at which time all the patients they have recruited will be included in that group.

**Intervention**

This is a complex intervention that includes the training of FPs and physician-patient interview based on the Ariadne principles; the effectiveness of the intervention has been studied in the MULTIPAP RCT [23, 36, 37]. The training includes activities related to basic concepts of multimorbidity, the appropriateness of prescriptions, adherence to treatment, the ARIADNE principles, and shared doctor-patient decision-making. All participating physicians will receive this training with the objective of incorporating patient-centred interviews into their routine clinical practice. This would allow the effect of the training to be isolated from the use of a DSS.

**Intervention group**

Several key elements of the intervention must be highlighted:

1. Clinical data will be reviewed and registered by FPs in the electronic case report forms (eCRF) after recruitment in baseline visit.
2. Because of the natural separation between actual electronic health records and electronic case report forms developed for the research project, final tool has been integrated into a dedicated eCRF system.
using a webservice WS4 version 1.2 of the CheckTheMeds® tool with the specific inputs reviewed by the FPs. This avoids barriers for FPs and the need for reintroducing double information to a separate system. Simple and detailed review of treatment plans has been incorporated. Simple review webservice outputs have been agreed after a Delphi technique with relevant stakeholders (primary care pharmacist, hospital pharmacist, family physicians, and researchers).

3. The web-based, user-initiated DSS provide FPs with drug-therapy information that is relevant to participating patients with polypharmacy on demand. After verifying the clinical data included in the eCRF (multimorbidity and polypharmacy corrected for patient-specific factors such as sex, renal function, age and frailty), this DSS provides health professionals with clinical scenarios to optimize treatment plans for patients, the number of STOPP/START and Beers criteria, drug interactions classified based on their potential severity (traffic light system), and adjustment of the medications to other relevant clinical variables.

4. FPs will be able to add and modify patient data in eCRF and able to review again treatment plans as many times as needed with up-to-date relevant information (new drugs, new diagnoses, change if laboratory findings about kidney function, etc.).

5. A specific training tool with video-recorded examples for clinical scenarios with treatment plans reviews appearing on first access to the tool and available for revising when needed as part of the formative intervention.

There are no restrictions regarding concomitant care during the trial. This intervention was developed in accordance with the recommendations and the taxonomy proposed by the Cochrane Effective Practice and Organization of Care Group (EPOC). The intervention is described in detail in Fig. 2, following the approach proposed by Perera et al. and the Template for Intervention Description and Replication (TIDieR) (Additional file 3) [38].

Control group
The patients in the control group will receive the usual clinical care based on the provision of advice and information and will be subjected to the examinations recommended in the guideline corresponding to each of the chronic diseases presented by the patient. Physicians will receive the same initial training programme as professionals in the intervention group.

Blinding
Due to the type of intervention, neither FPs and their patients nor the MULTIPAP Plus study team was blinded to the treatment allocation.

Variables
FPs will provide their data before the start of the study. Patient data will be collected by the recruiting FP, who will also be responsible for patient follow-up. All information will be recorded in a case report form designed for the study. Each FP will access the form from their personal computer through the project website using a personal identification code. Four visits were defined for patient data collection: baseline (T0), 6 months (T1), 12 months (T2), and 18 months (T3) (see Table 1).

Primary outcome variable
The primary outcome is a composite endpoint of hospital admission or death during the observation period.

| Time                  | Intervention | Control |
|-----------------------|--------------|---------|
| Baseline Visit (T0)   | 1            | 1       |
| Randomization         |              |         |
| Intervention          | Phase I      | Phase I |
|                       | a            | a       |
|                       | Phase II     |         |
| Usual care            | 5            |         |
| Measurement of results|              |         |

Fig. 2 Intervention
measured as a binary outcome. Primary outcome measures are recorded by the FPs when they occur or at follow-up visits.

**Secondary outcome variables**

- All cause mortality, non-elective hospital admission (number of episodes and duration)
- Related to the use of medication: Potentially inappropriate prescription will be evaluated in accordance with the BEER criteria [39] and the STOPP-START criteria [40]; medication safety will be measured as the incidence of adverse reactions and potentially dangerous interactions, classified based on the taxonomy proposed by Otero-López [41] as well as the incidence of adverse reactions; and adherence to treatment will be measured. Medication adherence was measured with the Morisky Medication Adherence score [42].
- Use of health services will be measured using records of unplanned and/or preventable hospitalizations as well as the use of emergency services and PC (FP and nurse).
- Quality of life will be measured using the EQ-5D-5L questionnaire [43, 44]. The differences in utility index between the intervention group and the control group at 18 months of follow-up will be used to determine the QALYs gained due to the intervention. The scores or utilities derived from the latest version of this tool, the EQ-5D-5L, have been proposed to provide information on economic evaluations of technologies.
- Disability will be measured using the WHODAS questionnaire [45] and number of fractures.
- For cost-utility, the National Health Service perspective will be adopted, with a time horizon of 2 years and a discount rate of 3%. The costs incurred will be the time dedicated to training required by the training programmes, the cost of the teaching staff, the time dedicated to doctor-patient interviews, and the rights to use of the tool (DSS). All costs derived from the intervention will be charged through an opportunity cost proxy: average salary by professional category. As “avoided costs” of the intervention, we will consider the price of the drugs discontinued (measured using the retail price) and the cost of the adverse reactions avoided. The EQ-5D-5L questionnaire will be used to estimate the utilities in both groups (intervention and control). The QALYs obtained with the intervention will be calculated and compared with the difference between the costs incurred and avoided.
- DSS usability will be measured from user analysis perspective and usability testing [46] to the direct users (FPs): (a) User analysis: this analyses user behaviour while interacting with a website. It is going to be realized non-obtrusively in the background by recording mouse movements and click behaviour to identify to what extent functions and website areas are accessed when reviewing treatments (Hotjar Tool); (b) usability using an ad hoc design with the Spanish-validated System Usability Scale (SUS) [47] and Computer Software Usability Questionnaire [48], DSS acceptability will be measured using records of actions performed with the

| Table 1 Visit plan |
|--------------------|
| T0 (baseline) | T1 (6 m*) | T2 (12 m*) | T3 (18 m*) | Responsible entity |
| Confirm inclusion/exclusion criteria | X | | | FP |
| Written informed consent | X | | | FP |
| Sociodemographic variables | X | | | FP |
| Morbidity variables and drug treatment plan | X | X | X | FP |
| Randomization of FP’s | X | | | RU |
| FP intervention (intervention group) | X | | | RT |
| Patient intervention (intervention group) | X | X | X | FP |
| Mortality | X | X | | RT/FP |
| Hospitalizations | X | X | | RT/FP |
| Functionality (WHODAS), falls, hip fractures | X | X | X | FP |
| Use of health services | X | X | X | RT |
| Quality of life | X | X | X | FP |
| Usability, adhesion, satisfaction | X | X | | TG |
| Costs | X | | | RT |

T: time, FP: family physician, RU: research unit, IG: intervention group, RT: research team, TG: technical group, m*: months from randomization.
CheckTheMeds® algorithm (number of changes) and a review of time invested per professional, and DSS satisfaction will be measured using an ad hoc questionnaire.

**Explanatory and adjustment variables**

a) Patient variables (first level)

- Sociodemographic: age, sex, nationality, region of residence, marital status, socioeconomic status (monthly salary expressed as multiples of minimum wage), family composition (number of people living in the household), indicators of subjective urban vulnerability, based on those collected by the National Health Survey to explore participants’ neighbourhood (noise level, odours, poor-quality drinking water, unclean streets, air pollution, lack of green areas, feral animals and crime), social support (Duke-UNC-11 Questionnaire adapted to Spanish [49]), profession, and social class [50].
- Morbidity: number and description of chronic diseases based on the International Classification of Diseases in Primary Care (ICPC) as per O’Halloran list [51].
- Pharmacotherapeutic treatment plan: number and type of drugs prescribed and active ingredient and dose of each drug.

b) FP variables (second level)

- Sociodemographic: age and sex.
- Professional performance: years of professional experience, resident mentor (yes/no), and average workload measured as average daily consultations per FP during the year prior to the start of the study.

**Oversight and monitoring**

**Roles and composition of the trial management committee**

**Principal investigators** Each participating region will have a lead investigator who will be the senior researcher receiving the public funding and will be responsible for identification and physician recruitment. Principal investigators will be steering committee members.

**Research physicians** Any of the physician recruiting patients involved in the data collection and completion of CRFs, along with the follow-up of study patients and adherence to study protocol and investigators brochure.

**Trial steering committee (TSC) (see title page for members)** All principal investigators will be steering committee members. Aragon region principal investigator will be national coordinator. Tasks: Agreement of final protocol. Recruitment of patients and liaising with principle investigator (PI). Reviewing progress of study and if necessary agreeing changes to the protocol and/or investigators brochure to facilitate the smooth running of the study.

**Trial management committee (TMC)** There will be a principal investigator, a research physician, a statistician, and a administrator at each region. Tasks are as follows: study planning, organization of steering committee meetings, provide annual risk report and ethics committee serious unexpected suspected adverse events, responsible for trial master file, budget administration and contractual issues with individual centres, advice for lead investigators, audit of 6 monthly feedback forms and decide when site visit to occur, assistance with international review and board/independent ethics committee applications, data verification, and randomization (this in Madrid Region).

**Data manager** There will be one per each region. Tasks are as follows: maintenance of trial IT system and data entry and data verification.

**Composition of the data monitoring committee, its role, and reporting structure**

A data monitoring committee (DMC) has been established based on the vital-status outcome measurement chosen and the long trial duration (18 months). The DMC is independent of the study organizers. For the data monitoring committee proposal, we have taken into account the distinguishing characteristics of pragmatic clinical trials [52–54]. This committee includes clinicians, biostatisticians, and ethical experts, and given the patient-centred outcomes focus of our trials [55, 56], a patient representative is incorporated to provide patient’s perspective. This will allow to review relative benefits, burdens, and potential harms of the interventions and will provide insight into the optimal ways for results sharing [57, 58] to participants and relevant patient group.

During the period of recruitment to the study, interim analyses will be supplied, in strict confidence, to the DMC, together with any other analyses that the committee may request. This may include analyses of data from other comparable trials. In the light of these interim analyses, the DMC will advise the TSC. The frequency of interim analyses will depend on the judgement of the Chair of the DMC, in consultation with the TSC. However, we anticipate that there might be one interim
analysis at 12 months after randomization and one final analysis at 18 months. The interim analysis will be performed by an independent statistician, blinded for the treatment allocation. The statistician will report to the independent DMC.

**Statistical analysis**
All analyses will be carried out according to the intention-to-treat principle, with a statistical significance at $p < 0.05$.

Description of the baseline characteristics means and standard deviations for the quantitative variables and absolute and relative frequencies for the qualitative variables, with their corresponding 95% confidence intervals (95% CIs). Likewise, the characteristics of those patients who leave the study will be described, including the reason for loss during follow-up.

Basal comparisons between groups will be performed using statistical tests for independent samples (Student’s $t$-test or chi-squared test). Tests for related samples (ANOVA for repeated measures) will be used to analyse changes within groups and between visits.

**Analysis of main effectiveness**
The difference in percentages in the composite endpoint of hospital admission or death to 18 months with its corresponding 95% CI. Multilevel analysis will be adjusted considering the combined final variable as the dependent variable; the baseline variables of the patient (first level), the professional (second level), and the intervention group as independent fixed effect variables; and the clustering by physician as a random factor. We will use multiple imputation by chain equations including baseline, 6-month, and 12-month data as available, intervention group, stratification and minimization variables, and other covariates that were informative of missingness. A sensitivity analysis will be conducted to assess whether conclusions may change if assumptions about missing data change.

**Analysis of secondary effectiveness**
The same analysis will be performed for 12 months. Missing data for professionals and/or patients will be replaced with the most recent reference or available data. For the remaining secondary effectiveness analyses, the difference in means or proportions will be calculated based on the characteristics of the variables (T3–T0) and (T2–T0) between groups using the appropriate statistical tests, and an explanatory model will be adjusted using the same methodology applied to the main outcome variable.

**Estimated quality-adjusted life years (QALYs)** gained at the population level, with corresponding 95% CI, as determined using parametric methods and bootstrap techniques. Given the 2-year time horizon, a discount rate of 3% will be applied.

**Calculation of the cost-utility ratio**
A cost-utility ratio will be estimated by dividing the total costs by the sum of the potential gains expressed in QALYs. A multivariate sensitivity analysis will be performed by varying the value of the costs with the appropriate distributions within the range of uncertainty. The benefits (QALYs) will also vary with the most suitable distribution in the 95% CIs of the estimates. It will also be included in the sensitivity analysis.

**User analysis and usability testing analysis**
Descriptive statistics will be used to analyse CSUQ an SUS scores according to the formal way of analysis to compare between participant groups (FPs) to take into account gender and age differences [59] in usability. No repeated-measurements neither pre-post test will be analysed.

**Discussion**
This pragmatic clinical trial will involve the participation of FPs from over 130 PC health centres in different geographic areas of Spain, thus ensuring a high level of external validity, given that the PC model implemented throughout the country is relatively homogeneous.

Among the possible limitations or biases of our study, we take into consideration that professionals who agree to participate may be more motivated, leading to observer bias (Hawthorne effect). Those professionals more involved in the work will probably make greater use of the DSS than if it were established under normal conditions. If the tool is effective, we might observe an overestimation of the effect that if applied to routine clinical practice would be more limited. This could lead to a greater effectiveness than would be obtained under normal conditions, but it is expected that when randomization is performed after the inclusion of patients in the study, the magnitude of the difference between the two groups will be minimized. Additionally, all physicians will have previously received the training intervention. In this way, it will be ensured that all physicians receive the same training and share the same knowledge of the study, thus reducing performance bias.

The use of a composite endpoint as hospital admission or death is proposed as recommended by some European studies, in order to compare the results with these studies [28, 60, 61].

The intervention cannot be blinded, which could influence the results. However, because the variables can be obtained from records, those who carry out the analysis and their interpretation will not know to which group the patient belongs. In turn, to avoid possible
contamination of the professionals in the control group, the intervention group will be advised of their commitment to confidentiality. The control group may use the DSS to review the treatments of the patients included in the study at the end of follow-up for a similar period of time. The expected changes in quality of life are small, but their measurement allows incorporating outcome variables reported by the patient and calculating utilities.

**Trial status**
Protocol Version Rev.0 (19.03.2019) + Anexo 2 Rev.0 (05.04.2019). Recruitment started on February 27, 2020. Approximate date for end of recruitment February 28, 2022.

**Abbreviations**
FP: Family physician; PC: Primary care; SR: Systematic review; ICT: Information and Communication Technologies; FPs: Family physicians; DSS: Decision support system; eCRF: Electronic case report form; QALY: Quality-adjusted life year; MIP: Potentially inappropriate prescription

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s13063-022-06293-x.

**Acknowledgements**
MULTIPAP Plus Group
Collaborating Investigators: MULTIPAP Plus in Primary Care Health Centres (PCHC):
- **PCHC Teatinos**: Esperanza Mora-García. Unidad de Farmacia Inmaculada Moraga Ropero (Michel-Bertevas, Rafael Ángel Maqueda. Miguel Domínguez-Santaella. Martín-Lomeña. del Cura-González
- **PCHC Actur Norte (Zaragoza)**: Ascensión Saura Campos, María Bergoña Abadía-Taiba. PCHC Alcorcón (Teruel): Carmen Sánchez-Celaya-del-Pozo. PCHC Benidín (Huesca): Ana Carmen Giménez-Baratche. PCHC Borja (Zaragoza): Lara Sanz-Burgos. PCHC Bujaraloz (Zaragoza): Mercedes Abad-Royo. PCHC Castejón (Zaragoza): Carmen Camats-Franco. José Manuel Cortés-Pellicer, Paula Herrero-Solsossa, Aida Moreno-Juste. PCHC Caspe (Zaragoza): Miguel Guir-Camps, Nima Peyman-Fard-Shafi-Tabatabai. PCHC Delicias Norte (Zaragoza): Mª Teresita Delgado-Mamoqui. PCHC Delicias Sur (Zaragoza): Mercedes López-Echevarría. José Carmona-Pérez. PCHC Epila (Zaragoza): Fernando Barrera-Linares, Sandro Daniel Carrillo-Soria, Ana Belén Esteban-Gimeno, Beatriz López-Alonso. PCHC Fuentes Norte (Zaragoza): Anabel Hernández-Bono, Enriqueta Martínez-Ayala, Adriana Martínez-Manoer. PCHC Gràfols (Huesca): Raquel Martínez-Sánchez. PCHC La Almumia (Zaragoza): Yolanda Naya-Mateu. PCHC La Jota (Zaragoza): María Lourdes Clemente-Jiménez, María Paz Leon-Martínez, Lilianna Mauelua, Mª Rosario Sanjuan-Cortés, Elisa Pilar Salazar-González. PCHC Perpetuo Socorro (Huesca): Mª Elena Charte-Alegre, Mª Jesús Mur-Lazuela, Mónica Pascual-Franco. PCHC Rebolosa (Zaragoza): Pilar Arizon-Deza, Carmen García-Gutiérrez-Muñoz, Teresa García-Ruiz, Gloria Navarro-Aznárez. PCHC San José Centro (Zaragoza): Carlos Alcobear-Pérez. PCHC San José Sur (Zaragoza): María Paz Navarro-Taulet. PCHC San Pablo (Zaragoza): Mª Lucasa-Serrano, Ana Cristina Maza-Invernón, Jaime Pedro-Sánchez. PCHC Tauste (Zaragoza): José Miguel Bufeuel-Granados. PCHC Teruel Centro (Teruel): Ainaña Alonso-Vallujuena, Mónica Lasheri-Barriol. PCHC Torrelo-La Paz (Zaragoza): Isabel Ibarrondo-Fernández-Ladreda, Rosa Mª López-Aylón, María José Rodríguez-Fabre, Isabel Rubio-Gutiérrez, Selma Valverde-Aranda.

Ana Cristina Bandrés-Liso, Antonio Ponce-Falcó (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, REDISSEC ISCIII, Aragon Health Service (SALUD), Zaragoza, Spain), Kevin Biek-Bueno (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, Teaching Unit of Preventive Medicine and Public Health, Miguel Servet University Hospital, Zaragoza, Spain), Amaia Calderon-Larraga (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, RICAPPS-REDISSEC ISCIII, Zaragoza, Spain, Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm University, Stockholm, Sweden), Mabel Cano-del-Pozo (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón. General Directorate of Health Care, Department of Health, Government of Aragon), Mercedes Clerencia-Sierra (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, REDISSEC ISCIII. Miguel Servet University Hospital, Zaragoza, Spain), Jesús Díez-Manglano (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, Royo Villanueva Hospital, Aragon Health Service (SALUD), Zaragoza Spain), Inmaculada Guerrero-Ferández-de-Alba (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, REDISSEC ISCIII, Department of Preventive Medicine, San Cecilio University Hospital, Granada, Spain), Ignatios Ioakeim-Skoufa (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón. WHO Collaborating Centre for Drug Statistics Methodology, Department of Drug Statistics, Norwegian Institute of Public Health, NO-0213 Oslo, Norway), Javier Marta-Moreno (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, REDISSEC ISCIII. Miguel Servet University Hospital, Aragon Health Service (SALUD), Zaragoza, Spain), (Madrid): PCHC Alcalá (Fuencarral): David Santos-Muñoz. PCHC Castilla la Nueva (Fuente el Dolor): María De Los Àngeles Miquel-Abanto. PCHC Dr. Mendiguchia Cariche (Leganes): Francisco García-De-Blas, Juan Carlos García-Alvarez, Sonia Redondo-de-Pedro. PCHC El Greco (Getafe): Carlos Fendos González-García, Carolina Peñal-Zagun, Esther Gomez-Suarez, Fernanda Morales-Ortiz, Isabel Ferrer-Zapata, Yolanda Beatriz Sánchez-Fernández, Yolanda Fernández-Fernández. PCHC El Soto (Móstoles): Esther Bario-Higuelo, EmaVera Rojo-Delgado, Irisa Lopez-Larrazoay. PCHC Embajadores (Madrid): María Luz Sezana. PCHC Ensenche de Vallecres (Madrid): Julio Cesar Fernández-Sánchez. PCHC Entrevías (Madrid): María Teresa San-Miquel-Marinero. PCHC Federica Monterrey (Madrid): María Jesús Fidalgo-Baz, Sara Ares-Blanco. PCHC General Ricardos (Madrid): Jorge Ignacio Gómez-Ciriano, José Damián García-Ranz, Laura Santos-Franco, María Celeste García-Galeano, Raquel Mateo-Fernández, Sara Morcillo-Cebolla, Tomás Rossignoli-Fernández. PCHC Ilba (Madrid): Jorge Olmedo-Galindo. PCHC Juan de la Cerva (Getafe): Marta Pinel-González, Rosa

University; María del Pilar Barnesinto-Fonsenca (Fundación CUDECA, Instituto de Investigación Biomédica de Málaga – IBIMA-, Universidad de Málaga, Spain).
Maria Redondo-Romerio. PCHC Las Américas (Parla): Admaloy Helena Estrada-Leon, Belén Muñoz-Gómez, Blanca Sanz-Pozo, Claudia López-Marcos, Enrique Rodríguez-De-Mingo, Juan Carlos Moreno-Fernández, Luis Enrique Morales-Cobos, María Del Prado García-García-Alcaraz, Marisol Lorenzo-Borda. PCHC Los Caleas (Madrid): Vera González-García. PCHC Los Rosales (Madrid): María Del Pilar Muñoz-Molina, Yasmín Drak-Hernández, PCHC Los Yébenes (Madrid): Alejandro Rabanal-Basalo, Ana María Abad-Esteban, María De Los Ángeles Rollan-Hernández, Mónica Fuster-Tozer, Raquel Carretero-Ramos, Rebeca Mielgo-Salvador. PCHC María Ángeles López (Leganés): Ana Sosa-Alonso, Carmen María Muros-Muñoz, Jeanett Dolores Sánchez-Yépez, María Cristina Cárceces-Cortés, María Palomos Moro-Peláez, María Pastor-Estebeanez, Mercede-Mesd Fernández-Girón. PCHC María Jesus Hernés (Leganés): Antonia Pérez-De-Colosoa-Zul, Esteban Pérez-Gutiérrez, Isabel Tejeiro-García, Jaime Innerarity-Martínez, Mar Álvarez-Villalba, Margarita Gómez-Barroso, María Del Mar Escobar-Gallegos, María Jesús Bedoya-Frutos, Marta Inmaculada Del-Olmo-Ribagorda, Petra María Cortés-Durán, Pilar Tardáguila-Lobato, Raquel Yolanda Terrón-Barbosa. PCHC Panaderas (Fuentelabricada): Antonio Ramos-Blanco, Aránzazu López-Villálvila, Beatriz Cinta-Bella, Cristian Varela-Varela, Francisca García-Rodríguez, Gema María Sáez-Ladera, Guillermina López-Fernández, Lourdes Orozco-Barrenechea, María Beogoña Zafra-De-Gea, Nuria García-Arpa, Tamara Ewa-Barnas. PCHC Parque Lorancán (Fuentelabricada): Ana Isabel Carbonero-Martín, María José Rojas-Giraldo. PCHC San Blas (Parla): Alberto Cotillas-Rodero. PCHC San Carlos (El Esclerita): Beatriz López-Serrano. PCHC San Cristóbal (Madrid): María Del Carmen Rodríguez-Fernández. PCHC Sector III (Getafe): Carmelina Sanz-Velasco, Jose Ignacio Aza-Pascual-Salcedo. PCHC Villanueva de Salvanés: Carolina López-Olmeda. PCHC Consultorio Sevilla la Nueva: Estrella Gutiérrez-Ocana. PCHC Consutorio Torrejón de la Calzada: Raquel García-Ocaña. Research Unit GAAP: Teresa Sanz-Cuesta, Ricardo Rodríguez-Barrientos, Milagros Rico-Blázquez, Mª Gloria Anza-Caridi, Mª Eugenia Tello Bernabé. Subdirección General Farmacia: Angel Mataix-SanJuan, Marta Alcaraz-Bonjorno. Servicio de Epidemiología Área 2: Mariel Morey Montalvo Servicio de Epidemiología Área 2: Mercedes Rummy-Zaruelo. Sistemas de información GAAP: Luis Sánchez-Perruca. Universidad St Andrews: Amaya Azcoaga-Lorenzo, Virginia Hernández-Santiago. (País Vasco): Centro de Salud de Alza (Gipuzkoa): Rafael Rotaache-del-Campo.

**Authors’ contributions**

APT, IDC, and DPT conceived the study and participated in its design and coordination in collaboration with JALR and FLF. LAGF, VPS, MJBZ, MDS, EPB, BPP, MAPS, MRB, MCJ, CLH, AGM, FGR, RMG, AGH, MGC, JMIF, JMM, AM, and CM have participated in different phases of the protocol study design. IDC and JALR wrote the first draft, and APT, DPT, FLF, and EPB collaborated in the writing of the manuscript. All authors from the MULTIPAP plus group have read and approved the final manuscript.

**Funding**

This study was funded by Instituto de Salud Carlos III (isciii) [file number PI18/01812, PI18/01303 y PI18/01515, RD16/0001/0004, RD16/0001/0005, RD16/0001/0006] and co-funded by the European Regional Development Fund 'A way to shape Europe; Research, Development and Innovation National Plan 2013-2016.' The funding body had no role either in the design of the study and collection, analysis, interpretation of data, or writing the manuscript.

**Availability of data and materials**

The data that support the findings of this study will be available from research unit univestigación.ap@salud.madrid.org, but restrictions apply to the availability of these data, which were used under licence for the current study, and so are not publicly available. However, each new project based on these data must be previously submitted to CEICA for approval. Data will be however available from the authors upon reasonable request and with permission of the project’s principal investigators (Alexandra Prados-Torres at spradosiac@aragon.es, Daniel Prados-Torres at daniel.prdos@salud.madrid.org). The datasets analysed during the current study and statistical code are available from the corresponding author on reasonable request, as is the full protocol.

**declarations**

**Ethics approval and consent to participate**

This trial will respect the basic ethical principles of autonomy, beneficence, justice, and no maleficence, and its development will follow the principles of Good Clinical Practice, the principles stated in the most recent Declaration of Helsinki (Seoul 2013), and the Oviedo Convention (1997). The project will be evaluated by the corresponding author on reasonable request, as is the full protocol.

**Consent for publication**

Not applicable

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Research Unit, Primary Care Assistance Management, Madrid Health Service, Madrid, Spain. 2Department of Medical Specialties and Public Health, School of Health Sciences, Rey Juan Carlos University, Madrid, Spain. 3Research Network on Health Services in Chronic Diseases REDISSEC-ISCIII, Madrid, Spain. 4Instituto de Investigación Sanitaria Gregorio Marañón (ISGM), Madrid, Spain. 5Research Networks Health Outcomes-Oriented Cooperative on Chronicity, Primary Care and Health Promotion RICORS RICAPPS, ISCIII, Madrid, Spain. 6Ricardos General Health Center, Madrid Health Service, Madrid, Spain. 7Multiprofessional Family and Community Care Teaching Unit of the Málaga-Gualdalhorce Health District, Málaga, Spain. 8Biomedical Research Institute of Malaga (IBIMA), Málaga, Spain. 9University of Malaga, Málaga, Spain. 10San Pablo Primary Care Health Centre, Aragon Health Service, Zaragoza, Spain. 11University of Zaragoza, Zaragoza, Spain. 12Extreme Chron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, Miguel Sierra University Hospital, Zaragoza, Spain. 13Torrelo-La Paz Primary Care Health Centre, Aragon Health Service (SALUD), Zaragoza, Spain. 14La Victoria Health Center, Málaga-Gualdalhorce Health District, Málaga, Spain. 15Primary Care Pharmacy Service Zaragoza II, Aragon Health Service, Zaragoza, Spain. 16Health Center Campillos, Malaga North District (Antequera), Málaga, Spain. 17Primary HealthCare Research and Innovation Foundation FiLBAP, Madrid, Spain. 18Delicias Sur Primary Care Health Centre, Aragon Health Service (SALUD), Zaragoza, Spain. 19Preventive Medicine Service, University Hospital Alcorcon Foundation, Madrid, Spain. 20Multiprofessional Family and Community Care Teaching Unit West, Madrid, Spain. 21Department of Family Medicine, National University Health System, Singapore, Singapore. 22Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. 23Department of General Practice and Family Medicine, Medical Faculty OWL, University of Bielefeld, Bielefeld, Germany.

Received: 18 February 2022 Accepted: 9 April 2022 Published online: 09 June 2022

**References**

1. World Health Organization (WHO). World report on ageing and health. Luxembourg: World Health Organization, 2015.
2. Prados-Torres A, Poblador-Plou B, Calderón-Larrañaga A, Gimeno-Fellu LA, González-Rubio F, Poncel-Falcó A, et al. Multimorbidity patterns in primary care: interactions among chronic diseases using factor analysis. Gagnier JJ. PLoS One. 2012;7:e22190. https://doi.org/10.1371/journal.pone.0022190.
41. Otero López MJ, Codina Jané C, Tamés Alonso MJ, Pérez EM. Medication errors: standardizing the terminology and taxonomy. Ruiz Jarabo 2000 grand results. Farm Hosp. 2003;27:137–49. https://doi.org/10.1097/00005650-198601000-00007.

42. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74. https://doi.org/10.1097/00005650-198601000-00007.

43. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-SD (EQ-SD-SL). Qual Life Res. 2011;20(10):1727–36. https://doi.org/10.1007/s11136-011-9903-x.

44. Herdman M, Badia X, Berra S. EuroQol-SD: a simple alternative for measuring health-related quality of life in primary care. Aten Primaria. 2001;28(6):25–30. https://doi.org/10.1016/S0212-6567(01)70406-4.

45. Organización Mundial de la Salud OMS. Medición de la Salud y la Discapacidad Manual para el Cuestionario de Evaluación de la Discapacidad de la OMS (WHOQOL 2.0). Ginebra: Organización Mundial de la Salud; 2015.

46. Reichenpfader D, Glauser R, Dugas M, Denecke K. Assessing and improving the usability of the Medical Data Models portal. Stud Health Technol Inform. 2020;271:199–206. https://doi.org/10.3233/SHTI200097.

47. Del Rocío S-GM, Loaeza LM, Lazaro-Carrera LS, Ramírez BB, Rodríguez AV, Peralta-Pediero ML, et al. Spanish version of the system usability scale for the assessment of electronic tools: Development and validation. JMIR Hum Factors. 2020;7(4):1–7. https://doi.org/10.2196/21161.

48. Hedleys Aguilar MI, De la Garza GA, Sánchez Miranda MP, Garza Villegas AA. Spanish language adaptation of the Computer Systems Usability Questionnaire CSUQ. RECI Rev Iberoam las Ciencias Comput e Informática. 2016;4:84.

50. Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, Ferrando J, Borrell C. Propuestas de clase social neoweberiana y neomarxista a partir de la Clasificación Nacional de Ocupaciones 2011. Gac Sanit. 2013;27:263–72. https://doi.org/10.1016/j.gaceta.2012.12.009.

51. del Cura-González et al. Trials (2022) 23:479

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.